Manuela Colla Carvalheiro
PhD (2011) in Pharmacy (Pharmaceutical Technology), Universidade de Lisboa
Auxiliar Researcher, Departmento de Farmácia Galénica e Tecnologia Farmacêutica
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
The core area of scientific activity is the comprehensive design, development and biological evaluation of lipid-based delivery systems to increase the therapeutic efficacy of bio and chemical entities, to reduce their toxicity, and allow their release at the specific site and in a controlled manner. Special interest has been focused on the treatment of leishmania infections, particularly through non-invasive routes of administration. Other interests include the development of cells-based in vitro models for the evaluation of drug susceptibility.
Simões MG, Alves P, Carvalheiro M, Simões PN. Stability effect of cholesterol-poly(acrylic acid) in a stimuli-responsive polymer-liposome complex obtained from soybean lecithin for controlled drug delivery. Colloids Surf B Biointerfaces 2017; 152: 103-113.
Fernandes AR, Jesus J, Martins P, Figueiredo S, Rosa D, Martins LM, Corvo ML, Carvalheiro MC, Costa PM, Baptista PV. Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents. J Control Release 2017; 245: 52-61.
Raposo LR, Roma-Rodrigues C, Faísca P, Alves M, Henriques J, Carvalheiro MC, Corvo ML, Baptista PV, Pombeiro AJ, Fernandes AR. Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT. Vet Comp Oncol 2017; 15: 952-967.
Lopes RM, Pereira J, Esteves MA, Gaspar MM, Carvalheiro M, Eleutério CV, Gonçalves L, Jiménez-Ruiz A, Almeida AJ, Cruz ME. Lipid-based nanoformulations of trifluralin analogs in the management of Leishmania infantum infections. Nanomedicine. 2016; 11: 153-70.
Carvalheiro M, Esteves MA, Santos-Mateus D, Lopes RM, Rodrigues MA, Eleutério CV, Scoulica E, Santos-Gomes G, Cruz ME. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections. Eur J Pharm Biopharm. 2015; 93: 346-52.